科華生物(002022.SZ):自2014年至今一直無實際控制人,公司主營業務發展穩定
格隆匯6月7日丨科華生物(002022.SZ)接受機構調研,就“公司無實際控制人對公司的影響?格力地產全資子公司珠海保聯成為公司第一大股東後,對公司的定位?”
公司回覆稱,公司自2014年至今一直無實際控制人,公司主營業務發展穩定。格力地產通過全資子公司投資科華生物是其向生物醫藥和醫療健康領域佈局邁出實質性的步伐以及完善和擴展大健康板塊產業佈局的重要舉措。作為具有國資背景的格力地產,着眼於長期發展的目的,積極支持公司經營發展,對公司的長期穩定發展具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.